High-flow nasal cannula: evolving practices and novel clinical and physiological insights

Roca, Oriol; Li, Jie; Mauri, Tommaso

doi:10.1007/s00134-024-07386-8

Intensive Care Med

2024

DOI: 10.1007/s00134-024-07386-8

|View full text |Cite

High-flow nasal cannula: evolving practices and novel clinical and physiological insights

Oriol Roca,

Jie Li,

Tommaso Mauri

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

High-Flow Nasal Cannula in a Parkinson's Disease Patient Undergoing Deep Brain Stimulation in the Awake State

Gupta

2024

J Neuroanaesth Crit Care

View full text Add to dashboard Cite

The administration of deep brain stimulation (DBS) in patients with Parkinson's disease is commonly carried out with the patient in an awake state with conscious sedation. However, maintaining the airway and preventing desaturation can be challenging during the procedure. High-flow nasal cannula (HFNC) has been deemed to be a safe option for providing respiratory support in such patients, affording multiple benefits. We report the case of a 48-year-old male patient with Parkinson's disease who underwent DBS, during which HFNC was employed for respiratory support. The patient tolerated the HFNC well, and the procedure was conducted without any complications related to respiratory function.

show abstract

High-Flow Nasal Cannula in a Parkinson's Disease Patient Undergoing Deep Brain Stimulation in the Awake State

Gupta

2024

J Neuroanaesth Crit Care

View full text Add to dashboard Cite

show abstract

Long-Term High-Flow Nasal Therapy in Patients with Bronchiectasis of Different Severity: A Retrospective Cohort Study

Calabrese,

Nolasco,

Annunziata

et al. 2024

JCM

View full text Add to dashboard Cite

Background/Objectives: High-flow nasal therapy (HFNT) has been shown to reduce exacerbations of COPD and some evidence displays benefits in non-cystic fibrosis bronchiectasis (NCFB) patients. The present study aimed to compare the effectiveness of 12 months of home HFNT on the annual exacerbation rate between mild/moderate and severe NCFB patients, classified by the bronchiectasis severity index (BSI). Secondary outcomes were the evaluation of the dyspnea, pulmonary function, and sputum cultures in both groups. Methods: The study population included NCFB adult patients, with at least one severe exacerbation in the previous year on optimized therapy. NCFB exacerbations, dyspnea (mMRC score), pulmonary function test, and sputum cultures were assessed at baseline and after 12 months of HFNT. Results: A total of 86 NCFB patients were enrolled: 36 in the mild/moderate (BSI < 9) and 50 in the severe (BSI ≥ 9) group. A significant improvement in the annual exacerbation rate was found in both BSI ≥ 9 (p < 0.0001) and BSI < 9 cohorts (p < 0.0001), with a between-group difference of −1 (95% CI: −2 to 0) exacerbations per year (p = 0.0209). The change in the annual exacerbation rate was significantly correlated with BSI (ρ = −0.26, p = 0.0151) and with HFNT daily use (ρ = −0.22, p = 0.0460). The mMRC score significantly improved by −2 points (95% CI: −2 to −1) after treatment in both groups (p < 0.0001). The percentage of patients with P. aeruginosa colonization decreased from 34.9% to 27.9%. Conclusions: Long-term HFNT reduces the annual exacerbation rate in NCFB patients and its effectiveness increases alongside disease severity and daily use of HFNT.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

High-flow nasal cannula: evolving practices and novel clinical and physiological insights

Cited by 2 publications

References 17 publications

High-Flow Nasal Cannula in a Parkinson's Disease Patient Undergoing Deep Brain Stimulation in the Awake State

High-Flow Nasal Cannula in a Parkinson's Disease Patient Undergoing Deep Brain Stimulation in the Awake State

Long-Term High-Flow Nasal Therapy in Patients with Bronchiectasis of Different Severity: A Retrospective Cohort Study

Contact Info

Product

Resources

About